SheMed Raises $50 Million Series A, Achieves Unicorn Status to Expand Personalised Women’s Health Services
London-based women’s health technology company SheMed has secured $50 million in Series A funding, a milestone round that values the startup at $1 billion, making it a unicorn less than two years after its founding. The capital will support the company’s expansion across the United Kingdom, scale its clinical and technology teams, enhance its digital healthcare platform, and fund ongoing research into women’s metabolic health and personalised treatment models.
Founded in April 2024 by sisters Olivia and Chloe Ferro, SheMed has quickly emerged as a leader in personalised care for women, particularly through its GLP-1-focused weight management and wellness programme. Within a year, the company enrolled more than 60,000 members, driven by demand for tailored healthcare that combines medical oversight with continuous digital support. Its platform integrates diagnostics, personalised treatment planning, and weekly app-based progress tracking to deliver care adapted to each individual’s biology and health profile.
The funding reflects growing investor confidence in digital women’s health solutions that move beyond one-size-fits-all models toward data-driven, clinically precise care. SheMed’s approach begins with an at-home diagnostic kit and blood test reviewed by independent physicians, followed by tailored treatment plans that include GLP-1-based medications alongside lifestyle and wellness support, monitored via weekly check-ins on its platform.
SheMed’s leadership says the capital will be directed toward scaling operations across the UK, strengthening clinical infrastructure, growing its medical and technology workforce, and enhancing its data-driven healthcare capabilities. The investment will also support expanded research efforts and patient experience initiatives designed to improve access to high-quality personalised care for women, particularly in areas where traditional healthcare models have fallen short or failed to account for female-specific biology and metabolic responses.
Co-founder and CEO Olivia Ferro highlighted the funding as validation of the company’s mission to redefine women’s healthcare. SheMed was built in response to her own experiences navigating undiagnosed health issues and seeking care that was both personalised and empathetic. According to Ferro, the unicorn valuation underscores the significant unmet demand for health solutions that recognise women’s individual needs and deliver outcomes grounded in clinical precision rather than broad categories.
Chloe Ferro, co-founder and President, noted that many women turn to the company because it offers a supportive, tailored healthcare journey addressing not only weight management but also broader metabolic and hormonal health concerns. SheMed is preparing to publish results from what it describes as the first female-focused GLP-1 clinical study, which is expected to provide insights into hormonal and metabolic responses and help refine future treatment pathways.
While SheMed has not publicly disclosed all individual investors in its Series A round, the size and valuation of the funding signal strong backing from venture capital and strategic investors who see long-term potential in women-centric health platforms that leverage data, technology, and clinical oversight to drive personalised care.
Health technology analysts note that SheMed’s success comes amid a broader surge in investment in women’s health and personalised digital care solutions within the UK and Europe. Companies focusing on preventative, data-driven healthcare models have attracted significant capital, reflecting shifting investor priorities toward long-term, high-impact health outcomes rather than purely transactional telehealth services.
The company’s rapid growth and unicorn milestone place it among a growing cohort of health tech startups reshaping care delivery through integrated digital platforms, hybrid clinical models, and precision prescribing tailored to individual patient data. As SheMed scales operations and expands research, it aims to deepen its footprint in personalised women’s health while addressing historically overlooked gaps in clinical evidence and care pathways.
By combining personalised diagnostics, continuous remote monitoring, and curated treatment plans, SheMed is positioning itself to contribute not only to improved health outcomes for women but also to the broader transformation of preventive and personalised healthcare—a sector of increasing importance as demand for tailored solutions continues to rise.
